Humanwell Healthcare (Group) Co. Ltd. has synthesized prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) and EP4 antagonists reported to be useful for the treatment of cancer, inflammation, neurodegeneration, autoimmune and cardiovascular diseases.